Skip to main content
SpringerLink
Log in

Nonlinear protein binding and enzyme heterogeneity: Effects on hepatic drug removal

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The kinetics of substrate removal by the liver and the resulting nonlinear changes in unbound fraction along the flow path at varying input drug concentrations were examined by a model simulation study. Specifically, we varied the binding association constant, KA,and the MichaelisMenten constants (Km and Vmax)to examine the steady state drug removal (expressed as hepatic extraction ratio Eand changes in drug binding for (i) unienzyme systems and (ii) simple, parallel metabolic pathways; zonal metabolic heterogeneity was also added as a variable. At low KA, Edeclined with increasing input drug concentration, due primarily to saturation of enzymes; only small differences in binding were present across the liver. At high KA,a parabolic profile for Ewith concentration was observed; changes in unbound fraction between the inlet and the outlet of the liver followed in parallel fashion. Protein binding was the rate-determining step at low input drug concentrations, whereas enzyme saturation was the rate-controlling factor at high input drug concentration. Heterogeneous enzymic distribution modulated changes in unbound fraction within the liver and at the outlet. Despite marked changes in unbound fraction occurring within the liver for different enzymic distributions, the overall transhepatic differences were relatively small. We then investigated the logarithmic average unbound concentration and the length averaged concentration as estimates of substrate concentration in liver in the presence of nonlinear drug binding. Fitting of simulated data, with and without assigned random error (10%), to the Michaelis-Menten equation was performed; fitting was repeated for simulated data obtained with presence of a specific inhibitor of the high-affinity, anteriorly distributed pathway. Results were similar for both concentration terms: accurate estimates were obtained for anterior, high affinity pathways; an over estimation of parameters was observed for the lower affinity posteriorly distributed pathways. Improved estimations were found for posteriorly distributed pathways upon inhibition with specific inhibitors; with added random error, however, the improvement was much decreased. We applied the method for fitting of several sets of metabolic data obtained from rat liver perfusion studies performed with salicylamide (SAM) (i) without and (ii) with the presence of 2,6-dichloro-4-nitrophenol (DCNP), a SAM sulfation inhibitor. The fitted results showed that SAM sulfation was a high-affinity high-capacity pathway; SAM glucuronidation was of lower affinity but comparable capacity as the sulfation pathway, whereas SAM hydroxylation was of lower affinity and lower capacity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. W. J. Jusko and M. Gretch. Plasma and tissue protein binding of drugs in pharmaco-kinetics.Drug Metab. Rev. 5:43–140 (1976).

    Article  CAS  PubMed  Google Scholar 

  2. M. Rowland. Protein binding and drug clearance.Clin. Pharmacokin. 9(Suppl.1):10–17 (1984).

    Article  CAS  Google Scholar 

  3. S. Øie. Drug distribution and binding.J. Clin. Pharmacol. 26:583–586 (1986).

    Article  PubMed  Google Scholar 

  4. J. J. Coffey, F. J. Bullock, and P. T. Schoenemann. Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination.J. Pharm. Sci. 60:1623–1628 (1971).

    Article  CAS  PubMed  Google Scholar 

  5. G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance.Clin. Pharmacol. Ther. 18:377–390 (1975).

    CAS  PubMed  Google Scholar 

  6. P. J. McNamara, G. Levy, and M. Gibaldi. Effect of Plasma protein and tissue binding on the time course of drug concentration in plasma.J. Pharmacokin. Biopharm. 7:195–206 (1979).

    Article  CAS  Google Scholar 

  7. J.-D. Huang and S. Øie. Hepatic elimination of drugs with concentration-dependent serum protein binding.J. Pharmacokin. Biopharm. 12:67–81 (1984).

    Article  CAS  Google Scholar 

  8. G. M. Rubin and T. N. Tozer. Hepatic binding and Michaelis-Menten metabolism of drugs.J. Pharm. Sci. 75:660–663 (1986).

    Article  CAS  PubMed  Google Scholar 

  9. U. Klotz, K. H. Antonin, and P. R. Bieck. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.J. Pharmacol. Exp. Ther. 199:67–73 (1976).

    CAS  PubMed  Google Scholar 

  10. U. W. Wiegard, K. L. Hintze, J. T. Slattery, and G. Levy. Protein binding of several drugs in serum and plasma of healthy subjects.Clin. Pharmacol. Ther. 27:297–300 (1980).

    Article  Google Scholar 

  11. W. L. Schary and M. Rowland. Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver prepara-tion.J. Pharmacokin. Biopharm. 11:225–243 (1983).

    Article  CAS  Google Scholar 

  12. M. Otagiri, T. Maruyama, T. Imai, A. Suenaga, and Y. Iniamura. A comparative study of the interaction of warfarin with human α1-acid glycoprotein and human albumin.J. Pharm. Pharmacol. 39:416–420 (1987).

    Article  CAS  PubMed  Google Scholar 

  13. W. D. Wosilait and S. Garten. Computation of unbound anticoagulant values in plasma.Res. Commun. Chem. Pathol. Pharmacol. 3:285–291 (1972).

    CAS  PubMed  Google Scholar 

  14. S. Øie and G. Levy. Effect of plasma protein binding on elimination of bilirubin.J. Pharm. Sci. 64:1433 (1975).

    Article  PubMed  Google Scholar 

  15. R. Gugler and G. Mueller. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.Br. J. Clin. Pharmacol. 5:441–446 (1978).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. X. Xu, B. K. Tang, and K. S. Pang. Metabolism of salicylamide in the once-through perfused rat liver preparation. Compensation by glucuronidation and hydroxylation for sulfation.Fed. Proc. 44:1256 (1985).

    Google Scholar 

  17. X. Xu, B. K. Tang, and K. S. Pang. Sequential metabolism of salicylamide exclusively to gentisamide-5-glucuronide and not gentisamide sulfate conjugates in the single passin situ perfused rat liver.J. Pharmacol. Exp. Ther. 253:963–973 (1990).

    Google Scholar 

  18. X. Xu and K. S. Pang. Hepatic modeling of metabolite kinetics in sequential and parallel pathways: salicylamide and gentisamide metabolism in perfused rat liver.J. Pharmacokin. Biopharm. 17:645–671 (1989).

    Article  CAS  Google Scholar 

  19. M. E. Morris and K. S. Pang. Competition between two enzymes for substrate removal in liver: Modulating effects due to substrate recruitment of hepatocyte activity.J. Pharmacokin. Biopharm. 15:473–496 (1987).

    Article  CAS  Google Scholar 

  20. R. S. Proire and H. E. Rosenthal. A statistical method for the estimation of binding parameters in a complex system.Anal. Biochem. 70:231–240 (1976).

    Article  Google Scholar 

  21. J. B. Whitlam and K. F. Brown. Computation of multiclass drug-protein binding parameters.Int. J. Pharm. 5:49–56 (1980).

    Article  CAS  Google Scholar 

  22. D. Z. D'Argenio and A. Schumitsky. A program package for simulation and parameter estimation in pharmacokinetic systems.Comput. Prog. Biochem. 9:115–134 (1979).

    Article  Google Scholar 

  23. Y. C. Tsang and J. Thiessen. Competitive binding of salfamethazine and its N-acetylated metabolite.Biopharm. Drug Dispos. 10:465–479 (1989).

    Article  CAS  PubMed  Google Scholar 

  24. L. Ott.An Introduction to Statistical Method and Data Analysis, Praeger Publishers, New York, 1984, pp. 431–434.

    Google Scholar 

  25. K. Yamaoka, T. Nakagawa, and T. Uno. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.J. Pharmacokin. Biopharm. 6:165–175 (1978).

    Article  CAS  Google Scholar 

  26. B. K. Martin. Potential effect of the plasma proteins on drug distribution.Nature 207:274–276 (1965).

    Article  CAS  PubMed  Google Scholar 

  27. G. Scatchard. The attractions of proteins for small molecules and ions.Ann. N. Y. Acad. Sci. 51:660–672 (1949).

    Article  CAS  Google Scholar 

  28. J. A. Jansen. Influence of plasma protein binding kinetics on hepatic clearance assessed from a “tube” model and a “well-stirred”model.J. Pharmacokin. Biopharm. 19:15–26 (1981).

    Article  Google Scholar 

  29. R. H. Smallwood, G. W. Mihaly, R. A. Smallwood, and D. J. Morgan. Effect of a protein binding change on unbound and total plasma concentrations for drugs of intermediate hepatic extraction.J. Pharmacokin. Biopharm. 16:529–542 (1988).

    Article  CAS  Google Scholar 

  30. U. F. Legier, F. J. Frey, and L. Z. Benet. Prednisolone clearance at steady-state in humans.J. Clin. Endocrinol. Metab. 55:762–767 (1982).

    Article  Google Scholar 

  31. M. Chiba and K. S. Pang. Effects of protein binding on 4-methylumbelliferyl sulfate desulfation kinetics in perfused rat liver.J. Pharmacol. Exp. Ther. In Press, 1993.

  32. L. Bass, S. Keiding, K. Winkler, and N. Tygstrup. Enzymatic elimination of substrates flowing through the intact liver.J. Theoret. Biol. 61:393–409 (1976).

    Article  CAS  Google Scholar 

  33. K. Winkler, L. Bass, S. Keiding, and N. Tygstrup. The effect of hepatic perfusion on the assessment of kinetic constants. In F. Lundquist and N. Tygstrup (eds.),Regulation of Hepatic Metabolism, Munksgaard, Copenhagen, 1974, pp. 797–807.

    Google Scholar 

  34. M. E. Morris, V. Yuen, B. K. Tang, and K. S. Pang. Competing pathways in drug metabolism. I. Effect of input concentration on the conjugation of gentisamide in the once-throughin situ perfused rat liver preparation.J. Pharmacol. Exp. Ther. 245:614–624 (1988).

    CAS  PubMed  Google Scholar 

  35. M. E. Morris, V. Yuen, and K. S. Pang. Competing pathways in drug metabolism. II. An identical, anterior enzymatic distribution for 2-and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver.J. Pharmacokin. Biopharm. 16:633–656 (1988).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, University of Toronto, 19 Russell Street, M5S 2S2, Toronto, Ontario, Canada

    Xin Xu & K. Sandy Pang

  2. Faculty of Mathematics, University of Toronto, Toronto, Ontario, Canada

    Paul Selick

  3. Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

    K. Sandy Pang

  4. Drug Metabolism, Merck Research Laboratories, 19486, West Point, Pennsylvania

    Xin Xu

Authors
  1. Xin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Selick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Sandy Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by the Medical Research Council, Canada, and the National Institutes of Health (U.S.A.). Dr. Pang is a recipient of a Faculty Development Award from the Medical Research Council, Canada (DG-263).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, X., Selick, P. & Pang, K.S. Nonlinear protein binding and enzyme heterogeneity: Effects on hepatic drug removal. Journal of Pharmacokinetics and Biopharmaceutics 21, 43–74 (1993). https://doi.org/10.1007/BF01061775

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01061775

Key words

Search

Navigation